vs
AtriCure, Inc.（ATRC）与Liberty Broadband Corp（LBRDA）财务数据对比。点击上方公司名可切换其他公司
Liberty Broadband Corp的季度营收约是AtriCure, Inc.的1.8倍（$261.0M vs $141.2M），Liberty Broadband Corp净利率更高（146.7% vs 0.1%，领先146.7%），AtriCure, Inc.同比增速更快（14.3% vs 6.1%），过去两年AtriCure, Inc.的营收复合增速更高（10.2% vs 4.3%）
AtriCure是一家专注于心房颤动及相关心脏病症治疗的医疗设备企业，研发并生产创新外科手术工具与疗法，主要服务北美、欧洲、亚太地区的医院、心脏外科中心及医疗机构，为微创心脏手术提供高效可靠的适配解决方案。
本公司是一家覆盖英、荷、美三地的跨国电信企业，注册地为百慕大，在伦敦、阿姆斯特丹、丹佛设有总部，旗下拥有多家对应司法辖区的运营主体，其中英国主体为公开上市实体，2005年由自由媒体国际业务板块与UnitedGlobalCom合并成立。
ATRC vs LBRDA — 直观对比
营收规模更大
LBRDA
是对方的1.8倍
$141.2M
营收增速更快
ATRC
高出8.2%
6.1%
净利率更高
LBRDA
高出146.7%
0.1%
两年增速更快
ATRC
近两年复合增速
4.3%
损益表 — Q1 FY2026 vs Q2 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $141.2M | $261.0M |
| 净利润 | $108.0K | $383.0M |
| 毛利率 | 77.4% | — |
| 营业利润率 | 23.0% | 15.7% |
| 净利率 | 0.1% | 146.7% |
| 营收同比 | 14.3% | 6.1% |
| 净利润同比 | — | 96.4% |
| 每股收益（稀释后） | $0.00 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ATRCLBRDA
| Q1 26 | $141.2M | — | ||
| Q4 25 | $140.5M | — | ||
| Q3 25 | $134.3M | — | ||
| Q2 25 | $136.1M | $261.0M | ||
| Q1 25 | $123.6M | $266.0M | ||
| Q4 24 | $124.3M | $263.0M | ||
| Q3 24 | $115.9M | $262.0M | ||
| Q2 24 | $116.3M | $246.0M |
净利润ATRCLBRDA
| Q1 26 | $108.0K | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $-267.0K | — | ||
| Q2 25 | $-6.2M | $383.0M | ||
| Q1 25 | $-6.7M | $268.0M | ||
| Q4 24 | — | $291.0M | ||
| Q3 24 | $-7.9M | $142.0M | ||
| Q2 24 | $-8.0M | $195.0M |
毛利率ATRCLBRDA
| Q1 26 | 77.4% | — | ||
| Q4 25 | 75.0% | — | ||
| Q3 25 | 75.5% | — | ||
| Q2 25 | 74.5% | — | ||
| Q1 25 | 74.9% | — | ||
| Q4 24 | 74.5% | — | ||
| Q3 24 | 74.9% | — | ||
| Q2 24 | 74.7% | — |
营业利润率ATRCLBRDA
| Q1 26 | 23.0% | — | ||
| Q4 25 | 1.8% | — | ||
| Q3 25 | 0.2% | — | ||
| Q2 25 | -4.5% | 15.7% | ||
| Q1 25 | -4.8% | 16.2% | ||
| Q4 24 | -11.7% | 4.9% | ||
| Q3 24 | -6.4% | 11.5% | ||
| Q2 24 | -6.2% | 8.5% |
净利率ATRCLBRDA
| Q1 26 | 0.1% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | -0.2% | — | ||
| Q2 25 | -4.5% | 146.7% | ||
| Q1 25 | -5.5% | 100.8% | ||
| Q4 24 | — | 110.6% | ||
| Q3 24 | -6.8% | 54.2% | ||
| Q2 24 | -6.9% | 79.3% |
每股收益（稀释后）ATRCLBRDA
| Q1 26 | $0.00 | — | ||
| Q4 25 | $0.04 | — | ||
| Q3 25 | $-0.01 | — | ||
| Q2 25 | $-0.13 | $2.68 | ||
| Q1 25 | $-0.14 | $1.87 | ||
| Q4 24 | $-0.33 | $2.04 | ||
| Q3 24 | $-0.17 | $0.99 | ||
| Q2 24 | $-0.17 | $1.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $146.2M | $180.0M |
| 总债务越低越好 | $61.0M | $3.1B |
| 股东权益账面价值 | $491.7M | $10.4B |
| 总资产 | $644.0M | $16.6B |
| 负债/权益比越低杠杆越低 | 0.12× | 0.30× |
8季度趋势，按日历期对齐
现金及短期投资ATRCLBRDA
| Q1 26 | $146.2M | — | ||
| Q4 25 | $167.4M | — | ||
| Q3 25 | $147.9M | — | ||
| Q2 25 | $117.8M | $180.0M | ||
| Q1 25 | $99.9M | $226.0M | ||
| Q4 24 | $122.7M | $163.0M | ||
| Q3 24 | $130.3M | $168.0M | ||
| Q2 24 | $114.0M | $73.0M |
总债务ATRCLBRDA
| Q1 26 | $61.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $61.9M | — | ||
| Q2 25 | $61.9M | $3.1B | ||
| Q1 25 | $61.9M | $3.8B | ||
| Q4 24 | — | $3.8B | ||
| Q3 24 | $61.9M | $3.7B | ||
| Q2 24 | $61.9M | $3.6B |
股东权益ATRCLBRDA
| Q1 26 | $491.7M | — | ||
| Q4 25 | $491.9M | — | ||
| Q3 25 | $476.5M | — | ||
| Q2 25 | $464.5M | $10.4B | ||
| Q1 25 | $454.6M | $10.1B | ||
| Q4 24 | $461.0M | $9.8B | ||
| Q3 24 | $465.0M | $9.5B | ||
| Q2 24 | $462.1M | $9.3B |
总资产ATRCLBRDA
| Q1 26 | $644.0M | — | ||
| Q4 25 | $654.2M | — | ||
| Q3 25 | $635.4M | — | ||
| Q2 25 | $608.8M | $16.6B | ||
| Q1 25 | $591.6M | $17.0B | ||
| Q4 24 | $609.3M | $16.7B | ||
| Q3 24 | $615.1M | $16.3B | ||
| Q2 24 | $597.3M | $16.0B |
负债/权益比ATRCLBRDA
| Q1 26 | 0.12× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.13× | — | ||
| Q2 25 | 0.13× | 0.30× | ||
| Q1 25 | 0.14× | 0.38× | ||
| Q4 24 | — | 0.38× | ||
| Q3 24 | 0.13× | 0.39× | ||
| Q2 24 | 0.13× | 0.39× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $91.0M |
| 自由现金流经营现金流 - 资本支出 | — | $37.0M |
| 自由现金流率自由现金流/营收 | — | 14.2% |
| 资本支出强度资本支出/营收 | — | 20.7% |
| 现金转化率经营现金流/净利润 | — | 0.24× |
| 过去12个月自由现金流最近4个季度 | — | $-49.0M |
8季度趋势，按日历期对齐
经营现金流ATRCLBRDA
| Q1 26 | — | — | ||
| Q4 25 | $20.0M | — | ||
| Q3 25 | $26.7M | — | ||
| Q2 25 | $21.6M | $91.0M | ||
| Q1 25 | $-11.0M | $78.0M | ||
| Q4 24 | $5.8M | $1.0M | ||
| Q3 24 | $20.0M | $24.0M | ||
| Q2 24 | $7.4M | $27.0M |
自由现金流ATRCLBRDA
| Q1 26 | — | — | ||
| Q4 25 | $18.4M | — | ||
| Q3 25 | $24.1M | — | ||
| Q2 25 | $19.0M | $37.0M | ||
| Q1 25 | $-13.2M | $13.0M | ||
| Q4 24 | $3.1M | $-63.0M | ||
| Q3 24 | $16.4M | $-36.0M | ||
| Q2 24 | $5.0M | $-35.0M |
自由现金流率ATRCLBRDA
| Q1 26 | — | — | ||
| Q4 25 | 13.1% | — | ||
| Q3 25 | 18.0% | — | ||
| Q2 25 | 13.9% | 14.2% | ||
| Q1 25 | -10.7% | 4.9% | ||
| Q4 24 | 2.5% | -24.0% | ||
| Q3 24 | 14.1% | -13.7% | ||
| Q2 24 | 4.3% | -14.2% |
资本支出强度ATRCLBRDA
| Q1 26 | — | — | ||
| Q4 25 | 1.1% | — | ||
| Q3 25 | 1.9% | — | ||
| Q2 25 | 2.0% | 20.7% | ||
| Q1 25 | 1.8% | 24.4% | ||
| Q4 24 | 2.2% | 24.3% | ||
| Q3 24 | 3.1% | 22.9% | ||
| Q2 24 | 2.1% | 25.2% |
现金转化率ATRCLBRDA
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.24× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.17× | ||
| Q2 24 | — | 0.14× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ATRC
| Appendage management | $48.4M | 34% |
| Open ablation | $39.1M | 28% |
| Other | $25.0M | 18% |
| Pain management | $22.4M | 16% |
| Minimally invasive ablation | $6.4M | 5% |
LBRDA
暂无分部数据
